Dr. Guy Boivin is a professor in the Department of Pediatric of the Faculty of Medicine at Laval University. He held the Canada Research Chair in Emerging Viruses and Antiviral Resistance during 14 years, as well as a « Foundation » grant from the Canadian Institutes of Health Research (CIHR) for 7 years. He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccines in the elderly. 

Dr. Boivin is the author or co-author of over 400 scientific publications and 390 presentations at various international conferences and symposia. He has also contributed to the creation of 17 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections and of the company Vaxxel, that develops vaccines against respiratory viruses. He is the director of a NC3 laboratory that is operational since 2020, which expands the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (SARS-CoV-2). He is also the co-director of the international lab RespiVir jointly with Dr Rosa-Calatrava from Lyon, France. 

His research program focuses on the pathogenesis, treatment and prevention of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (human and avian flu). More recently, he has also been interested in SARS-CoV-2 responsible for COVID-19 and the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has completed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work has already had a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections. 

CHUL
2705, boulevard Laurier
R-0709
Québec, Québec
Canada G1V 4G2
395 entries « 1 of 40 »

Fortin N, Hénaut M, Goyette N, Maltais R, Sancéau JY, Marette A, Poirier D, Abed Y, Boivin G

A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses

Journal Article

J Med Virol, 96 (3), 2024.

Abstract | Links:

Gilca R, Amini R, Carazo S, Doggui R, Frenette C, Boivin G, Charest H, Dumaresq J

The Changing Landscape of Respiratory Viruses Contributing to Hospitalizations in Quebec, Canada: Results From an Active Hospital-Based Surveillance Study

Journal Article

JMIR Public Health Surveill, 10 , 2024.

Abstract | Links:

Ghesquiere L, Boivin G, Demuth B, Giguere Y, Forest JC, Hamelin ME, Muckle G, Carbonneau J, Bujold E

Impact of COVID-19 and Vaccination During Pregnancy on Placenta-Mediated Complications (COVIGRO Study)

Journal Article

J Obstet Gynaecol Can, 46 (4), 2024.

Abstract | Links:

Lapeyre L, Piret J, Rhéaume C, Pons V, Uyar O, Préfontaine P, Rivest S, Boivin G

Herpes Simplex Virus 1 Infection Does Not Increase Amyloid-β Pathology in APP/PS1 Mice

Journal Article

J Alzheimers Dis, 97 (1), 2024.

Abstract | Links:

Piret J, Boivin G

Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir

Journal Article

Infect Dis Rep, 16 (1), 2024.

Abstract | Links:

Piret J, Boivin G

The impact of trained immunity in respiratory viral infections

Journal Article

Rev Med Virol, 34 (1), 2024.

Abstract | Links:

Saim-Mamoun A, Carbonneau J, Rhéaume C, Abed Y, Boivin G

Viral Fitness of Baloxavir-Resistant Recombinant Influenza B/Victoria- and B/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs

Journal Article

Microorganisms, 11 (5), 2023.

Abstract | Links:

Eccles R, Boivin G, Cowling BJ, Pavia A, Selvarangan R

Treatment of COVID-19 symptoms with over the counter (OTC) medicines used for treatment of common cold and flu

Journal Article

Clin Infect Pract, 19 , 2023.

Abstract | Links:

Zinszer K, Charland K, Pierce L, Saucier A, McKinnon B, Hamelin MÈ, Cheriet I, Da Torre MB, Carbonneau J, Nguyen CT, De Serres G, Papenburg J, Boivin G, Quach C

Pre-Omicron seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and teenagers in Montréal, Canada

Journal Article

Int J Infect Dis, 131 , 2023.

Abstract | Links:

Royston L, Isnard S, Berini CA, Bu S, Lakatos PL, Bessissow T, Chomont N, Klein M, Lebouché B, de Pokomandy A, Kronfli N, Costiniuk CT, Thomas R, Tremblay C, Boivin G, Routy JP

Influence of letermovir treatment on gut inflammation in people living with HIV on antiretroviral therapy: protocol of the open-label controlled randomised CIAO study

Journal Article

BMJ Open, 13 (1), 2023.

Abstract | Links:

395 entries « 1 of 40 »
Signaler des ajouts ou des modifications

Active projects

  • CHOIR study: Children and Older Teens Immune Response to SARS-CoV-2 in Montreal, from 2021-12-01 to 2025-03-31
  • Évaluation des interactions entre des virus respiratoires, from 2022-02-01 to 2025-01-31
  • Identification of innate immune pathways as targets for immunomodulatory therapy in herpes simplex virus encephalitis, from 2023-10-01 to 2028-09-30
  • Laboratoire international associé (LIA) sur la pathogenèse, le traitement et la prévention des infections virales respiratoires (LIA RespiVIR), from 2021-07-27 to 2026-07-26
  • Mise au point d'un modèle animal pour l'infection avec le virus parainfluenza-3, from 2024-01-10 to 2026-01-10
  • Plateforme de laboratoire de niveau de confinement 3 pour la recherche sur les virus émergents, from 2023-01-31 to 2025-03-31

Recently finished projects

  • A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, from 2016-07-01 to 2023-06-30
  • Antiviral Resistance and Benefits of Combination Therapy for Influenza Viruses, from 2023-03-01 to 2024-02-29
  • Changement de paradigme dans la conduite d'essais cliniques, from 2021-04-01 to 2024-03-31
  • COVIGRO : Impact de la COVID-19 et du vaccin contre SARS-CoV-2 sur le développement placentaire et foetal, from 2021-12-01 to 2022-11-30
  • Hospital-based surveillance of influenza and routine monitoring of seasonal influenza vaccine effectiveness (VE), from 2020-11-01 to 2022-09-30
  • How to better manage infectious diseases in ER by triage with molecular mini-panels for the rapid detection of highly transmissible pathogens, from 2018-10-01 to 2022-09-30
  • Innovative therapeutic approaches for the 2019-novel coronavirus, from 2021-03-01 to 2024-03-31
  • Manufacturing of antigens and adjuvants for development of vaccines (MAAV), from 2021-07-01 to 2024-03-31
  • Relationship between COVID-19 and Parkinson’s disease in a mouse model, from 2022-10-01 to 2024-03-31
  • SO05 QC07, Sentinel surveillance for confirmed and suspected cases of covid-19/covsars-2 acute respiratory disease, covid-19 vaccine effectiveness and adverse events following sars-cv-2 vaccines: A study of the Serious Outcomes Surveillance, from 2021-04-01 to 2023-09-30
  • SO06 QC07 Sentinel Surveillance for Severe Outcomes of Laboratory-Confirmed Influenza in Adults for the Annual Influenza Season and for Confirmed and Suspected Cases Of Covid-19/Sars-Cov-2 Acute Respiratory Disease, Covid-19[...], from 2022-04-01 to 2023-03-31
Data provided by the Université Laval research projects registery